25-30% of adult population in the economically developed countries, including Ukraine, have arterial hypertension (AH). During the last 10-15 years there is high interest to metabolic disorders in arterial hypertension. By estimations of most experts, a leading factor in forming the symptoms of the metabolic syndrome is insulin resistance (IR). In development of AH in insulin resistance the complex influence of hyperinsulinemia and concomitant metabolic disorders play the leading part. That is why the search of etiological factors and links of pathogenis of AH is extremely actual since it can promote in determination of new ways of its effective pharmacotherapy. The article presents the own information about the changes of the life quality indexes of patients with arterial hypertension associated with insulin resistance when taking metabolic drugs (rosiglitazone, metformin and thyotriazolin) included in standard pharmacotherapy (candesartan + perindopril).
Key words: arterial hypertension, insulin resistance, standard pharmacotherapy, metformin, thyotriazolin
